Overview
- Roche reported ZUPREME-1 met its primary endpoint, with petrelintide producing up to 10.7% mean weight loss at week 42 versus 1.7% on placebo in 493 participants.
- Tolerability was described as placebo-like, including no vomiting and no gastrointestinal discontinuations at the maximally effective dose and a slightly lower adverse-event discontinuation rate than placebo.
- Zealand Pharma shares fell roughly 30–35% as analysts said results trailed the 12–15% they expected and lagged Eli Lilly’s amylin program, which has shown about 20% weight loss in Phase 2.
- Banks including JPMorgan, Jefferies, UBS, and Barclays called the data disappointing, and Cantor Fitzgerald cut its rating to Neutral, citing limited commercial differentiation.
- Observers flagged minimal separation across the top doses (about 10.2%–10.7%) and noted stronger responses in women, as Roche and Zealand point to full data later in 2026, ZUPREME-2 topline in H2 2026, a CT-388 combo trial this year, and a planned Phase 3 start in 2026.